Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 10/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.85 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.85 |
| ▸ | TSHR | P16473 | 1/20 | 0.85 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.85 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.83 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.83 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.83 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.83 |
| ▸ | MAPT | P10636 | 2/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.83 |
| ▸ | MEN1 | O00255 | 1/20 | 0.83 |
| ▸ | PTGES | O14684 | 1/20 | 0.83 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.83 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8645594 | 0.95 | AKR1C3 (1.00) | AKR1C3AKR1C2LMNACYP1A2CYP2D6 | |
| SCHEMBL12747878 | 0.92 | AKR1C3 (0.89) | AKR1C3AKR1C2LMNACYP1A2CYP2D6 | |
| SCHEMBL1082631 | 0.92 | HIF1A (1.00) | AKR1C3AKR1C2LMNACYP1A2CYP2D6 | |
| SCHEMBL11471705 | 0.91 | AKR1C3 (0.87) | AKR1C3AKR1C2LMNACYP1A2CYP2D6 | |
| Iodoindomethacin SCHEMBL13290295 | 0.91 | AKR1C3 (0.87) | AKR1C3AKR1C2LMNACYP1A2CYP2D6 | |
| Indomethacin SCHEMBL3518614 | 0.91 | PTGS2 (1.00) | AKR1C3AKR1C2LMNACYP1A2CYP2D6 | |
| Indomethacin SCHEMBL29525957 | 0.91 | PTGS2 (1.00) | AKR1C3AKR1C2LMNACYP1A2CYP2D6 | |
| SCHEMBL5796934 | 0.91 | AKR1C3 (1.00) | AKR1C3AKR1C2LMNACYP1A2CYP2D6 | |
| Indomethacin SCHEMBL9300 | 0.91 | PTGS2 (1.00) | AKR1C3AKR1C2LMNACYP1A2CYP2D6 | |
| Indomethacin SCHEMBL29353712 | 0.91 | PTGS2 (1.00) | AKR1C3AKR1C2LMNACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11738004-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
| US-11738004-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210251960-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2021-08-19 | — | — | US | disclosed |
| US-20190350903-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2019-11-21 | — | — | US | disclosed |
| US-10398678-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3078374-B1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | UNIV VANDERBILT (US) | 2019-06-19 | — | — | EP | disclosed |
| US-9895351-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2018-02-20 | — | — | US | disclosed |
| US-9895351-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170315127-A1 | TREATMENT OF METASTATIC PROSTATE CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-02 | — | — | US | disclosed |
| US-20160303082-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY | 2016-10-20 | — | — | US | disclosed |
| US-20140371261-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140088122-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2014-03-27 | — | — | US | disclosed |
| US-20140073611-A1 | METHODS FOR DRUG SCREEN USING ZEBRAFISH MODEL AND THE COMPOUNDS SCREENED THEREFROM | NATIONAL TAIWAN UNIVERSITY (TW) | 2014-03-13 | — | — | US | disclosed |
| US-20130172374-A1 | SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW PH AND METHODS OF USE THEREOF | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2013059245-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2013-04-25 | — | — | WO | disclosed |
| US-8163806-B2 | Controlled release of biologically active compounds from multi-armed oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120095217-A1 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2012-04-19 | — | — | US | disclosed |
| US-20120010284-A1 | CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | BEZWADA BIOMEDICAL, LLC (US) | 2012-01-12 | — | — | US | disclosed |
| US-20100151019-A1 | SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2007118276-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION(AMD) | PRANA BIOTECHNOLOGY LTD (AU) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350903-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | AKR1C3 1/4885AKR1C2 4/4885LMNA 2546/4885 |
| US-20100151019-A1 | SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF | CASR, TAS2R31, TAS2R45 | AKR1C3 1263/4885AKR1C2 1916/4885LMNA 1481/4885 |
| US-11738004-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | AKR1C3, AKR1C4, AKR1C1 | AKR1C3 1/4885AKR1C2 4/4885LMNA 2546/4885 |
| US-20140088122-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | ALDH1A2, AGER, PDE6C | AKR1C3 588/4885AKR1C2 1372/4885LMNA 400/4885 |
| US-20170315127-A1 | TREATMENT OF METASTATIC PROSTATE CANCER | AR, AKR1C3, AKR1C4 | AKR1C3 2/4885AKR1C2 4/4885LMNA 3095/4885 |
| US-10398678-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | AKR1C3, AKR1C4, AKR1C1 | AKR1C3 1/4885AKR1C2 4/4885LMNA 2546/4885 |
| US-20130172374-A1 | SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW PH AND METHODS OF USE THEREOF | CASR, TAS2R31, TAS2R45 | AKR1C3 1263/4885AKR1C2 1916/4885LMNA 1481/4885 |
| US-20140073611-A1 | METHODS FOR DRUG SCREEN USING ZEBRAFISH MODEL AND THE COMPOUNDS SCREENED THEREFROM | PLOD3, MYOC, SLTM | AKR1C3 3143/4885AKR1C2 2603/4885LMNA 72/4885 |
| US-20120010284-A1 | CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | MME, AADAC, LGMN | AKR1C3 1454/4885AKR1C2 1709/4885LMNA 1047/4885 |
| US-20140371261-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | AKR1C3 1/4885AKR1C2 4/4885LMNA 2306/4885 |
| US-20210251960-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | AKR1C3 1/4885AKR1C2 4/4885LMNA 2546/4885 |
| US-20160303082-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | AKR1C3 1/4885AKR1C2 4/4885LMNA 2546/4885 |
| US-20120095217-A1 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | FLI1, CDC73, FOS | AKR1C3 3710/4885AKR1C2 3372/4885LMNA 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.